参考文献/References:
[1].Mach F,Baigent C,Catapano AL,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J,2020,41(1):111-188.
[2].Grundy SM,Stone NJ,Bailey AL,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Circulation,2019,139(25):e1082-e1143.
[3].Sirtori CR. The pharmacology of statins[J]. Pharmacol Res,2014,88:3-11.
[4].Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study(4S)[J]. Lancet,1994,344(8934):1383-1389.
[5].Betters JL,Yu L. NPC1L1 and cholesterol transport[J]. FEBS Lett,2010,584(13):2740-2747.
[6].Cannon CP,Blazing MA,Giugliano RP,et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med,2015,372(25):2387-2397.
[7].P?rn A,Olsen D,Tuvikene J,et al. PCSK9 deficiency alters brain lipid composition without affecting brain development and function[J]. Front Mol Neurosci,2023,15:1-17.
[8].Schwartz GG,Steg PG,Szarek M,et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med,2018,379(22):2097-2107.
[9].Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[10].King DS,Wilburn AJ,Wofford MR,et al. Cognitive impairment associated with atorvastatin and simvastatin[J].Pharmacotherapy,2003,23(12):1663-1667.
[11].Galatti L,Polimeni G,Salvo F,et al. Short-term memory loss associated with rosuvastatin[J]. Pharmacotherapy,2006,26(8):1190-1192.
[12].Evans MA,Golomb BA. Statin-associated adverse cognitive effects:survey results from 171 patients[J]. Pharmacotherapy,2009,29(7):800-811.
[13].Muldoon MF,Barger SD,Ryan CM,et al. Effects of lovastatin on cognitive function and psychological well-being[J]. Am J Med,2000,108(7):538-546.
[14].Muldoon MF,Ryan CM,Sereika SM,et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults[J]. Am J Med,2004,117(11):823-829.
[15].Taylor BA,Dager AD,Panza GA,et al. The effect of high-dose atorvastatin on neural activity and cognitive function[J]. Am Heart J,2018,197:166-174.
[16].Samaras K,Makkar SR,Crawford JD,et al. Effects of statins on memory,cognition,and brain volume in the elderly[J]. J Am Coll Cardiol,2019,74(21):2554-2568.
[17].Trompet S,van Vliet P,de Craen AJ,et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study[J]. J Neurol,2010,257(1):85-90.
[18].Olmastroni E,Molari G,de Beni N,et al. Statin use and risk of dementia or Alzheimer’s disease:a systematic review and meta-analysis of observational studies[J]. Eur J Prev Cardiol,2022,29(5):804-814.
[19].Ott BR,Daiello LA,Dahabreh IJ,et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials[J].?J Gen Intern Med,2015,30(3):348-358.
[20].Cai SY,Gu X,Liu PJ,et al. Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia:a multicenter,randomized,double-blind,double-dummy,parallel-controlled phase Ⅲ clinical trial[J]. Zhonghua Xin Xue Guan Bing Za Zhi,2023,51(2):180-187.
[21].Qi L,Chen J,Li X,et al. Efficacy and safety of hybutimibe in combination with atorvastatin for treatment of hypercholesteremia among patients with atherosclerotic cardiovascular disease risk equivalent:a multicenter ,randomized,double-blinded phase Ⅲ study [J]. Front Cardiovasc Med,2022,9:888604.
[22].Robinson JG,Farnier M,Krempf M,et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J]. N Engl J Med,2015,372(16):1489-1499.
[23].Sabatine MS,Giugliano RP,Wiviott SD,et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J]. N Engl J Med,2015,372(16):1500-1509.
[24].Blom DJ,Harada-Shiba M,Rubba P,et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia:the ODYSSEY HoFH trial[J]. J Am Coll Cardiol,2020,76(2):131-142.
[25].Koh KK,Nam CW,Chao TH,et al. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan(ODYSSEY KT)[J]. J Clin Lipidol,2018,12(1):162-172.
[26].Han Y,Chen J,Chopra VK,et al. ODYSSEY EAST:alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China,India,and Thailand[J]. J Clin Lipidol,2020,14(1):98-108.
[27].Giugliano RP,Mach F,Zavitz K,et al. Cognitive function in a randomized trial of evolocumab[J]. N Engl J Med,2017,377(7):633-643.
[28].Gencer B,Mach F,Guo J,et al. Cognition after lowering LDL-cholesterol with evolocumab[J]. J Am Coll Cardiol,2020,75(18):2283-2293.
[29].O’Donoghue ML,Giugliano RP,Wiviott SD,et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease[J]. Circulation,2022,146(15):1109-1119.
[30].Raal FJ,Kallend D,Ray KK,et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia[J]. N Engl J Med,2020,382(16):1520-1530.
[31].Mefford MT,Rosenson RS,Cushman M,et al. PCSK9 variants,low-density lipoprotein cholesterol,and neurocognitive impairment:Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)[J]. Circulation,2018,137(12):1260-1269.
[32].Ghouse J,Ahlberg G,Bundgaard H,et al. Effect of loss-of-function genetic variants in PCSK9 on glycemic traits,neurocognitive impairment,and hepatobiliary function[J]. Diabetes Care,2022,45(1):251-254.
[33].Paquette M,Saavedra YGL,Poirier J,et al. Loss-of-function PCSK9 mutations are not associated with Alzheimer disease[J]. J Geriatr Psychiatry Neurol,2018,31(2):90-96.
[34].Yuet WC,Ebert D,Jann M. Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use:a narrative review[J]. Ther Adv Drug Saf,2021,12:2042098620959271.
[35].Engelberg H. Low serum cholesterol and suicide[J]. Lancet,1992,339(8795):727-729.
[36].Orth M,Bellosta S. Cholesterol:its regulation and role in central nervous system disorders[J]. Cholesterol,2012,2012:292598.
[37].Donegá S,Oba J,Maranh?o RC. Concentra??o sérica de lípides e apolipoproteína B em recém-nascidos [Concentration of serum lipids and apolipoprotein B in newborns][J]. Arq Bras Cardiol,2006,86(6):419-424.
[38].Faselis C,Imprialos K,Grassos H,et al. Is very low LDL-C harmful?[J]. Curr Pharm Des,2018,24(31):3658-3664.
[39].Schultz BG,Patten DK,Berlau DJ. The role of statins in both cognitive impairment and protection against dementia:a tale of two mechanisms[J]. Transl Neurodegener,2018,7:5.
[40].O’Connell EM,Lohoff FW. Proprotein convertase subtilisin/kexin type 9(PCSK9) in the brain and relevance for neuropsychiatric disorders[J]. Front Neurosci,2020,14:609.
相似文献/References:
[1]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(3):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[2]王申仪 阳军.基于RNA疗法在动脉粥样硬化性心血管疾病血脂管理的研究进展[J].心血管病学进展,2021,(4):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
Wang Shenyi,Yang Jun.Era of RNA-based Therapies in Lipid Management of?oronary Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(3):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
[3]刘力黎 陈诚 张丽敏.血脂水平与心房颤动相关性研究进展[J].心血管病学进展,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
LIU Lili,CHEN Cheng,ZHANG Limin.Serum Lipid Level and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(3):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
[4]许海南 龙明智.新型降脂药物干扰小RNA Inclisiran最新研究进展[J].心血管病学进展,2021,(7):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
XU Hainan,LONG Mingzhi.Small Interfering RNA Inclisiran[J].Advances in Cardiovascular Diseases,2021,(3):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
[5]袁荣辉 白春林.贝派地酸降脂疗效及安全性的研究进展[J].心血管病学进展,2021,(9):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
(.Shanxi Medical University,Taiyuan 0000,Shanxi,et al.YUAN Ronghui1,BAI Chunlin2[J].Advances in Cardiovascular Diseases,2021,(3):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[6]刘杨 陈明.冠心病的治疗新方向——PCSK9抑制剂[J].心血管病学进展,2021,(9):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
New Direction of Coronary Heart Disease TreatmentPCSK9 Inhibitors.E-mailchenmingcq77@163.com[J].Advances in Cardiovascular Diseases,2021,(3):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[7]黄橙 李波 李志勇 陈紫君.过低LDL-C在动脉粥样硬化性心血管疾病中潜在风险循证学证据[J].心血管病学进展,2023,(11):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]
Huang Cheng,Li Bo,Li Zhiyong,et al.The Evidence of the Potential Risk of Excessively Low Levels of LDL-C in ASCVD[J].Advances in Cardiovascular Diseases,2023,(3):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]